A5081767061- Genetic factors in colorectal cancer
- Cancer Genomics and Diagnostics
- Colorectal Cancer Treatments and Studies
- Colorectal Cancer Screening and Detection
- Gastric Cancer Management and Outcomes
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Mathematical Biology Tumor Growth
- Colorectal Cancer Surgical Treatments
- Health and Medical Research Impacts
- MRI in cancer diagnosis
- Pancreatic and Hepatic Oncology Research
- Immune cells in cancer
- PI3K/AKT/mTOR signaling in cancer
- Renal cell carcinoma treatment
- Lung Cancer Research Studies
- Esophageal Cancer Research and Treatment
- Colorectal and Anal Carcinomas
- Immunotherapy and Immune Responses
- Radiomics and Machine Learning in Medical Imaging
- Angiogenesis and VEGF in Cancer
- Advanced MRI Techniques and Applications
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Gastrointestinal Tumor Research and Treatment
- Immune Cell Function and Interaction
The University of Texas MD Anderson Cancer Center
2023-2025
Royal Marsden NHS Foundation Trust
2016-2023
Royal Marsden Hospital
2017-2023
University of Cambridge
2014-2021
Institute of Cancer Research
2018-2019
Cambridge University Hospitals NHS Foundation Trust
2010-2016
Breast Cancer Research Foundation
2013
Breakthrough
2013
Sequential profiling of plasma cell-free DNA (cfDNA) holds immense promise for early detection patient progression. However, how to exploit the predictive power cfDNA as a liquid biopsy in clinic remains unclear. RAS pathway aberrations can be tracked monitor resistance anti-EGFR monoclonal antibodies patients with metastatic colorectal cancer. In this prospective phase II clinical trial single-agent cetuximab
Locally advanced or metastatic squamous carcinoma of the anal canal (SCAC) has poor prognosis following platinum-based chemotherapy. Retifanlimab (INCMGA00012), a humanized monoclonal antibody targeting programmed death protein-1 (PD-1), demonstrated clinical activity across range solid tumors in trials. We present results from POD1UM-202 (NCT03597295), an open-label, single-arm, multicenter, phase II study evaluating retifanlimab patients with previously treated SCAC.Patients ≥18 years age...
Abstract Background Circulating tumour DNA (ctDNA) to detect minimal residual disease (MRD) is emerging as a biomarker predict recurrence in patients with curatively treated early stage colorectal cancer (CRC). ctDNA risk stratifies guide adjuvant treatment decisions. We are conducting the UK’s first multi-centre, prospective, randomised study determine whether de-escalation strategy using chemotherapy (ACT) decisions non-inferior standard of care (SOC) chemotherapy, measured by 3-year free...
Abstract Purpose: The absence of postoperative circulating tumor DNA (ctDNA) identifies patients with resected colorectal cancer (CRC) low recurrence risk for adjuvant chemotherapy (ACT) de-escalation. Our study presents the largest CRC cohort to date tissue-free minimal residual disease (MRD) detection. Experimental Design: TRACC (tracking mutations in cell-free predict relapse early cancer) included stage I III resectable CRC. Prospective longitudinal plasma collection ctDNA occurred pre-...
Abstract Purpose: Anti-EGFR mAbs are effective in the treatment of metastatic colorectal cancer (mCRC) patients. RAS status and tumor location (sidedness) predictive markers patients' response to anti-EGFR mAbs. Recently, low miR-31-3p expression levels have been correlated with clinical benefit from mAb cetuximab. Here, we aimed validate power a prospective cohort chemorefractory mCRC patients treated single-agent Experimental Design: was tested by situ hybridization (ISH) 91 pretreatment...
102 Background: Numerous studies have shown the clinical utility of ctDNA, a non-invasive biomarker to detect MRD and stratify CRC patients who are more likely relapse. We present an analysis detection in from prospective multicentre UK study, were monitored pre- post-surgery before adjuvant chemotherapy (ACT). Methods: The study recruited diagnosed with stage II-III (n=122), including subset rectal underwent tri-modality treatment (TMT). All had their primary tumor resected 56% (68/122)...
[Figure: see text].
Abstract Background: Novel immune strategies are needed to improve outcomes in patients (pts) with microsatellite-stable metastatic colorectal cancer (MSS mCRC). Our personalized peptide vaccine platform - termed NeoAg-VAX targets up 10 tumor-derived neoantigens per pt. We hypothesize that this combined anti-PD-1 can enhance antitumor immunity and revert the cold status of MSS CRC tumor microenvironment (TME). Methods: This is a single-center, non-randomized, open-label, investigator-led...
Abstract: With the increasing understanding of biology disease and development targeted therapy, there has been a paradigm shift in treatment clear cell metastatic renal carcinoma (mRCC). Traditionally patients with RCC have treated immunotherapy which limited efficacy. The multikinase inhibitors sunitinib, sorafenib pazopanib, VEGF antibody bevacizumab combination interferon mTOR inhibitor temsirolimus all shown to prolong progression-free survival phase III studies. Here we review another...
Abstract Anticancer immunity is predicated on leukocyte migration into tumors. Once recruited, leukocytes undergo substantial reprogramming to adapt the tumor microenvironment. A major challenge in field distinguishing recently recruited from resident In this study, we developed an intravascular Ab technique label circulating mouse before they migrate tissues, providing unprecedented insight kinetics of recruitment. This approach unveiled role progression using a preclinical model lung...
Mismatch repair-deficient (MMRd) colorectal cancers (CRCs) have high mutation burdens, which make these tumours immunogenic and many respond to immune checkpoint inhibitors. The MMRd hypermutator phenotype may also promote intratumour heterogeneity (ITH) cancer evolution. We applied multiregion sequencing CD8 programmed death ligand 1 (PD-L1) immunostaining systematically investigate ITH how genetic landscapes coevolve. All cases had truncal burdens. Despite pervasive ITH, driver aberrations...
TPS4120 Background: Adjuvant chemotherapy (ACT) is routinely offered to patients with high risk (HR) stage II or III CRC following potentially curative surgery. Over 50% of and > 80% are cured by surgery alone but being exposed unnecessary short- long-term side effects. Post-operative ctDNA identifies minimal residual disease (MRD) after in CRC. Our national study, TRACC, compares guided versus standard care (SoC) decision making undergoing ACT. Methods: This a UK-wide, multi-centre,...
4015 Background: PLATFORM is a prospective, open-label, multicentre, adaptive phase II trial assessing maintenance therapy in patients (pts) with OG adenocarcinoma after platinum-based first-line induction chemotherapy. HER2 negative pts were initially randomised 1:1:1:1:1 to surveillance (A1), capecitabine (A2), durvalumab (A3), rucaparib (A4) and + ramucirumab (A5) added later as per design. Here we report the primary analysis of vs. surveillance. Methods: Pts upon achieving response or...
It is widely believed that small rectal tumors are more likely to have a good response neoadjuvant treatment, which may influence the selection of patients for 'watch and wait' strategy.The aim this study was investigate whether there relationship between baseline tumor length on magnetic resonance imaging (MRI) chemoradiotherapy.The 96 with locally advanced cancer randomised (2:1-intervention:control) in TRIGGER feasibility where eligible. Baseline defined as maximal cranio-caudal MRI (mm)...
Our website uses cookies to enhance your experience. By continuing use our site, or clicking "Continue," you are agreeing Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications Network Open Cardiology Dermatology Health Forum Internal Medicine Neurology Ophthalmology Otolaryngology–Head & Neck Surgery Pediatrics Psychiatry Archives of (1919-1959) JN Learning / CMESubscribeJobsInstitutions LibrariansReprints Permissions Terms Use Privacy...
282 Background: Advanced OGA patients (pts) are treated with platinum-based 1 st line chemotherapy but the role of maintenance therapy once disease control is obtained unknown. Methods: PLATFORM a prospective, open-label, adaptive phase II trial assessing in OGA. HER2 negative pts advanced achieving response or stable on completion were initially randomised to surveillance (A1), capecitabine (A2) and durvalumab (A3). Rucaparib (A4) capecitabine+ramucirumab (A5) subsequently added as part...
548 Background: RAS status in tissue and/or liquid biopsies and tumour location (sidedness) are predictive markers of patients’ response to anti-EGFR mABs. MiR-31-3p expression has been correlated with clinical benefit from mABs chemotherapy. We aimed validate the power miR-31-3p a prospective cohort chemo-refractory mCRC patients treated single agent PROSPECT-C trial (NCT02994888). Methods: was tested by in-situ hybridization 91 pre-treatment (PT) core 45 patients. Sequential obtained PT,...
This study introduces the use of 'error-category mapping' in interpretation pharmacokinetic (PK) model parameter results derived from dynamic contrast-enhanced (DCE-) MRI data. Eleven patients with metastatic renal cell carcinoma were enrolled a multiparametric treatment effects bevacizumab. For purposes present analysis, DCE-MRI data two identical pre-treatment examinations analysed by application extended Tofts (eTM), using turn arterial input function (AIF), an individually-measured AIF...
As liver metastasis is the most common cause of mortality in patients with colorectal cancer, studying cancer (CLM) microenvironment essential for improved understanding tumor biology and to identify novel therapeutic targets.